Posted by Michael Wonder on 04 Sep 2020
Innovent announces NMPA granted marketing approval for Sulinno (adalimumab injection) in China
Innovent Biologics today announced that Sulinno (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration of China for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis in China.
Sulinno is Innovent's third monoclonal antibody drug approved by the National Medical Products Administration following Tyvyt (sintilimab injection) and Byvasda (bevacizumab injection).
The approval of Sulinno marks the expansion of Innovent's marketed products into the non-oncology field.
